The scientists found that an enzyme, called PLK1 (a kinase), is responsible for triggering the formation of the complex. PLK1 is active during normal mitosis, but for unknown reasons only induces ...

and polo-like kinase 1 (PLK1), driving pro-apoptotic cell death. The FDA's breakthrough device designation is given to devices that have the potential to provide effective treatment or diagnosis ...

Its main drug, onvansertib, is an oral Polo-like Kinase 1 (PLK1) inhibitor targeting KRAS-mutated colorectal cancer (mCRC) and other tumors. The company has shown promising clinical results and ...

Their pipeline is fully centered on Onvansertib, a small molecule aimed at inhibiting the polo-like kinase 1 (PLK1), for the treatment of RAS-mutated cancers, including metastatic colorectal ...

Steegmaier and colleagues, writing in Current Biology, have identified an inhibitor of polo-like kinase 1 (PLK1) — a serine/threonine-specific kinase that is highly expressed in malignant cells ...

Targeting this kinase can prevent DNA repair in cancer cells ... target other cell cycle pathways regulated by the PLK1 and PLK2 kinases. “When we look at the literature on different PLK1 ...

The high selectivity and temporal control of these chemical-genetic systems were crucial in revealing new roles of each kinase throughout the cell cycle. For instance, acute inhibition of Plk1 at ...

It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics.